Canopy Growth Corporation (CGC) is a NASDAQ-listed Canadian cannabis producer — a stock, not an exchange-traded fund — that has spent 2026 sliding toward multi-year lows. With shares changing hands near $0.69, the question of whether CGC can reach $1.70 hinges on a handful of widely diverging analyst price targets.
The central target reflects five current analyst price targets I collected and averaged, rather than a single published consensus. Roth MKM's Bill Kirk stands out with a Buy rating and a target near $3.60 (C$5.00, reiterated in mid-2026) — a notable outlier. Canaccord Genuity initiated with a Buy near $1.45, while Bernstein (Hold, about $1.24) and Alliance Global Partners' Aaron Grey (Hold, about $1.16) sit lower, and ATB Cormark upgraded to Buy near $1.01. Converted at roughly 1.38 Canadian dollars per U.S. dollar, the five targets average about $1.70.
That dispersion matters: most analysts cluster between $1.00 and $1.45, and the mean is pulled upward by Roth MKM's bullish outlier. The direction of revisions has been downward — Bernstein trimmed its target from C$2.53 to C$1.71, and Alliance Global Partners cut from C$1.80 to C$1.60 during 2026 — while Benchmark upgraded the stock from Sell to Hold in late 2025. Overall, the analyst consensus sits around Hold-to-Moderate Buy.
With shares near $0.69, reaching $1.70 requires roughly a 146% gain — a very large move by any measure. The stock trades in the lower reaches of its 52-week range of $0.65 to $2.38. Reaching the target would require not just a recovery in sentiment but a sustained improvement in the company's fundamentals, given that CGC remains unprofitable and its shares have repeatedly failed to hold rallies tied to U.S. regulatory headlines.
Canopy Growth's most recent quarterly results showed revenue up about 12.6% year over year, with an EPS (earnings per share) loss that narrowed by roughly half and an operating loss that shrank meaningfully — signs of improving operating leverage. Cost-control progress, share gains in Canadian adult-use cannabis, contributions from the MTL acquisition, and growing international medical and adult-use sales underpin the bullish case. Analysts with higher targets also point to the potential catalyst of U.S. federal cannabis rescheduling or broader legalization, which would expand Canopy's addressable market.
The obstacles are substantial. The company still posts net losses, and it has disclosed a material weakness in its financial controls — a red flag that raises reporting and capital-raising risk. Frequent equity offerings and follow-on share sales have diluted existing holders. Sector-wide cannabis weakness, delays in U.S. reform, intense competition, and valuation compression all weigh on the stock. Analysts with lower targets emphasize that near-breakeven adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) may support only a modest rebound, not a triple-digit one.
The 52-week low near $0.65 is the most relevant support level, and the stock is trading just above it. The psychologically important $1.00 level marks the first major resistance and the floor of most analyst targets, followed by prior consolidation zones near $1.40 to $1.45. The 52-week high of $2.38 stands as far overhead resistance. A decisive move above $1.00 would signal a meaningful shift in market structure, while a break below $0.65 would open fresh downside.
Most analyst price targets reflect a roughly 12-month research horizon, though individual firms differ. The next earnings report, expected around early November 2026, is the nearest catalyst, alongside guidance and any analyst revisions. Investors should also watch U.S. cannabis rescheduling developments, capital-raising announcements, margin trends, and whether the company can convert revenue growth into sustained positive cash flow.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, low-priced name like Canopy Growth, these signals can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals page to see how the tool is currently reading the tape.
Can Canopy Growth reach $1.70? The central target — the average of five current analyst price targets spanning roughly $1.00 to $3.60 — implies a very large 146% advance from around $0.69. The strongest supports are narrowing losses, improving operating leverage, and the potential catalyst of U.S. cannabis reform. The principal obstacles are persistent losses, a disclosed material weakness in financial controls, ongoing dilution, and an uncertain regulatory backdrop. The wide dispersion in analyst targets underscores how much depends on execution and policy timing; no outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CGC has been closely correlated with SNDL. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if CGC jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To CGC | 1D Price Change % | ||
|---|---|---|---|---|
| CGC | 100% | -4.88% | ||
| SNDL - CGC | 77% Closely correlated | -0.71% | ||
| TLRY - CGC | 75% Closely correlated | -7.02% | ||
| TRLV - CGC | 66% Closely correlated | +0.73% | ||
| ACB - CGC | 65% Loosely correlated | -0.97% | ||
| GLAS - CGC | 58% Loosely correlated | +2.60% | ||
More | ||||
| Ticker / NAME | Correlation To CGC | 1D Price Change % |
|---|---|---|
| CGC | 100% | -4.88% |
| CGC (4 stocks) | 62% Loosely correlated | +1.31% |
| Pharmaceuticals: Generic (81 stocks) | 7% Poorly correlated | -0.76% |